logo
  

NiSource Board Okays Separation Of Columbia Pipeline Group

NiSource Inc (NI) on Tuesday said its board has approved the separation of Columbia Pipeline Group ("CPG") from it through a distribution of CPG common stock to NiSource shareholders.

In connection with the board's approval, NiSource confirmed the distribution ratio, record date and distribution date for the separation.

As a result, the distribution of CPG stock is expected to be made after the close of trading on the New York Stock Exchange on July 1 to NiSource shareholders of record as of June 19.

On the distribution date, NiSource shareholders will receive one share of CPG common stock for every one share of NiSource common stock held as of the record date.

Following the distribution, CPG will be an independent, publicly traded company (CPGX), and NiSource will retain no ownership interest in CPG.

NiSource will remain one of the largest natural gas utility companies in the United States. NiSource will continue to be headquartered in Merrillville, Indiana.

CPG, based in Houston, after separation will include Columbia Gas Transmission, Columbia Gulf Transmission, Columbia Midstream Group, its ownership in Columbia Pipeline Partners (CPPL), and other natural gas pipeline, storage and midstream holdings currently owned by NiSource.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT